Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal irinotecan + S-1 versus liposomal irinotecan + 5-fluorouracil as second-line treatment for metastatic pancreatic cancer
2023-509463-24-01Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised trial in pancreatic adenocarcinoma (PDAC) comparing Onivyde + S-1 with Onivyde + fluorouracil (2 arms). Primary endpoint: Progression-free survival. Started Nov 2019; status: completed.
02
Drugs
irinotecantegafurfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2023-509463-24-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509463-24-01.